Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment;Perfil epidemiológico e fatores prognósticos no tratamento cirúrgico do adenocarcinoma de próstata clinicamente localizado

Revista do Colegio Brasileiro de Cirurgioes

Volumn 36, Issue 4, 2009, Pages 327-331

  Nassif, Aissar Eduardo ^a   Tâmbara Filho, Renato ^a   de Paula, Regina Xavier Gomes ^b   Taguchi, Willian Setsumi ^c   Pozzobon, Helio Jorge ^d  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b POSITIVO UNIVERSITY   (Brazil)

^c STATE UNIVERSITY OF MARINGÁ   (Brazil)

^d Hospital Santa Rita   (Brazil)

Author keywords

Adenocarcinoma epidemiology; Prognosis; Prostatectomy; Prostatic neoplasms; Prostatic neoplasms surgery

Indexed keywords

EID: 70450177323     PISSN: 01006991     EISSN: 18094546     Source Type: Journal    
DOI: 10.1590/s0100-69912009000400010     Document Type: Article

References (36)

1. Ercole B, Marietti SR, Fine J, Albertsen PC. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol. 2008; 180(4):1336-9; discussion 1340-1. Epub 2008 Aug 15.
2. Kuo NW, Lin HC, Lee HC. Physician clinical experience and inappropriate prostate specific antigen screening: evidence from an Asian country. J Urol. 2008; 180(5):1954-8; discussion 1958. Epub 2008 Sep 17.
3. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008; 148(6):435-48. Epub 2008 Feb 4. Erratum: Ann Intern Med. 2008; 148(11):888.
4. Elliott CS, Shinghal R, Presti JC Jr. Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes. J Urol. 2008; 180(4):1318-23; discussion 1323-4. Epub 2008 Aug 15.
5. Penson DF. Assessing the quality of prostate cancer care. Curr Opin Urol. 2008; 18(3):297-302.
6. Scale CD Jr, Dahm P. The critical use of population-based medical databases for prostate cancer research. Curr Opin Urol. 2008; 18(3):320-5.
7. Brasil-INCA, 2008. Ministério da Saúde. Secretaria de Atenção à Saúde. Instituto Nacional do Câncer. Coordenação de Prevenção e Vigilância. Estimativa 2008. Incidência de câncer no Brasil. Rio de Janeiro.
8. Stattin P, Holmberg E, Bratt O, Adolfsson J, Johansson JE, Hugosson J; National Prostate Cancer Register. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol. 2008; 180(6):2423-9; discussion 2429-30. Epub 2008 Oct 18.
9. Dham P, Yeung LL, Chang SS, Cookson MS. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. J Urol. 2008; 180(2):451-9; discussion 460. Epub 2008 Jun 11.
10. Freedland SJ, Krupski TL, Moul JW. Update on outcomes research databases in prostate cancer 2006. Curr Opin Urol. 2006; 16(3):168-72.
11. Klein EA, Bianco F, Serio AM, Eastham JA, Kattan MW, Pontes JE et al. Surgeon experience in strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol. 2008; 179(6):2212-6; discussion 2216-7. Epub 2008 Apr 18.
12. Neal DE. Can we accurately identify men with low risk prostate cancer? J Urol. 2008; 180(4):1217-8. Epub 2008 Aug 15.
13. Simone NL, Singh AK, Cowan JE, Soule BP, Caroll PR, Litwin MS. Pretreatment predictors of death from other causes in men with prostate cancer. J Urol. 2008; 180(6):2447-51; discussion 2451-2. Epub 2008 Oct 19.
14. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001; 58(6):843-8.
15. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150(1):110-4.
16. Partin AW, Carter HB, Cahn DW, Epstein JI, Oesterling JE, Rock RC et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990; 143(4):747-52.
17. Thompson I, Thrasher JB, Aus G, Buernett AL, Canby-Hagino ED, Cookson MS et al. Guidelines for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177(6):2106-31.
18. Wu AK, Cooperberg MR, Sadetsky N, Carroll PR. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol. 2008; 180(6):2415-22; discussion 2422. Epub 2008 Oct 18.
19. Kvale R, Auvinem A, Adami HO, Klint A, Hernes E, Moller B et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007; 99(24):1881-7. Epub 2007 Dec 11.
20. Teeter AE, Bañez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ et al. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from SEARCH database group. J Urol. 2008; 180(5):1980-4; discussion 1985. Epub 2008 Sep 17.
21. Billis A, Guimarães MS, Freitas LL, Meirelles L, Magna LA, Ferreira U. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol. 2008; 180(2):548-52; discussion 552-3. Epub 2008 Jun 11.
22. Nam RK, Jewett MA, Krahn MD. Prostate cancer: 2. Natural history. CMAJ. 1998; 159(6):685-91.
23. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111(1):58-64.
24. Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol. 2000; 24(4):563-9.
25. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999; 281(15):1395-400.
26. Epstein JI, Carmichael MJ, Partin AW, Walsh PC. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenic and clinical implications. J Urol. 1994; 151(6):1587-92.
27. Fergunson JK, Bostwick DG, Suman V, Zincke H, Oesterling JE. Prostate-specific antigen detected prostate cancer: pathological characteristics of ultrasound visible versus ultrasound invisible tumors. Eur Urol. 1995; 27(1):8-12.
28. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin Tables) based on cases from 2000 to 2005. Urology. 2007; 69(6):1095-101.
29. D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol. 2006; 176(6 Pt 2):S11-5.
30. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 1995; 294(4):433-9.
31. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90(10):766-71.
32. Mulhall JP. Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions. J Urol. 2009; 181(2):462-71. Epub 2008 Dec 13.
33. Alibhai SM, Leach M, Tomlinson G. Impact of hospital and surgeon volume on mortality and complications after prostatectomy. J Urol. 2008; 180(1):155-62; discussion 162-3. Epub 2008 May 15.
34. Wei JT, Dunn RL, Marcovich R, Montie JE, Sanda MG. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol. 2000; 164(3 Pt 1):744-8.
35. Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008; 17996):2181-5; discussion 2185-6. Epub 2008 Apr 18.
36. Penson DF, Chan JM; Urologic Diseases in America Project. Prostate cancer. J Urol. 2007; 177(6):2020-9.